Lung Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Lung Therapeutics is a pharmaceutical company that researches and develops novel therapeutics for the treatment of lung diseases. Read more

39 Followers on Owler
39 Followers on Owler
39 Followers on Owler
39 Followers on Owler

Lung Therapeutics is a pharmaceutical company that researches and develops novel therapeutics for the treatment of lung diseases. Read more

Brian Windsor's photo - CEO of Lung Therapeutics

CEO

Brian Windsor

CEO Approval Rating

89/100

Founded:

2013

Status:

PrivateIndependent Company

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Sanovas is the top competitor of Lung Therapeutics. Sanovas is headquartered in Petaluma, California, and was founded in 2009. Sanovas competes in the Health Care Services field. Sanovas generates 80% the revenue of Lung Therapeutics.

Nuvaira is perceived as one of Lung Therapeutics's biggest rivals. Nuvaira was founded in Minneapolis, Minnesota} in 2008. Nuvaira operates in the Health Care Equipment industry. Compared to Lung Therapeutics, Nuvaira generates $6M less revenue.

FibroGen is seen as one of Lung Therapeutics's top competitors. FibroGen is a Public company that was founded in San Francisco, California in 1993. Like Lung Therapeutics, FibroGen also operates in the Biotechnology field. FibroGen has 485 more employees vs. Lung Therapeutics.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is ReViral a competitor of Lung Therapeutics?

Acquisitions

No recent acquisitions found related to Lung Therapeutics

Lung Therapeutics Funding History

$2.6M$16.9M$20.8M$56.8M$57.2M

Since Lung Therapeutics was founded in 2013, it has participated in 6 rounds of funding. In total Lung Therapeutics has raised $57.2M. Lung Therapeutics' last funding round was on Aug 2020 for a total of $300.2K

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
Aug 2020
$300.2K
Debt - PPP (CARES Act)
Apr 2020
$150K - $350K

U.S. Small Business Administration.

Series C
May 2019
$36M
Unattributed
Jun 2018
$3.9M
-
Series B
Feb 2016
$14.3M

Since Lung Therapeutics was founded in 2013, it has participated in 6 rounds of funding. In total Lung Therapeutics has raised $57.2M. Lung Therapeutics' last funding round was on Aug 2020 for a total of $300.2K

Investments

No recent investments found related to Lung Therapeutics

Lung Therapeutics News

August 11, 2020Statesman

Austin's TFF Pharmaceuticals raises $25.9M with stock offering

Austin-based TFF Pharmaceuticals said Tuesday that it has raised $25.9 million to expand its product ... See more »
June 5, 2019The Business Journals

Lung Therapeutics releases details about $36M funding

Lung Therapeutics is developing two primary drugs: LTI-01 to treat loculated pleural effusion, a seri... See more »
June 4, 2019FinSMEs

Lung Therapeutics Raises $36M in Series C Financing

Lung Therapeutics, Inc., an Austin, TX-based...... See more »
February 6, 2019The Business Journals

Austin drug developer Lung Therapeutics adds to C-suite

Lung Therapeutics has hired Charles Garner as its new chief financial officer as it pushes ahead with... See more »
February 4, 2019Talent4Boards

Lung Therapeutics appoints R.A. Session to its Board of Directors and announces Chuck Gardner as new CFO

Talent4Boards - Great Talent builds Great Boards- USA, TX - Lung Therapeutics, Inc., a clinical stage... See more »
October 5, 2018BioPortfolio

Lung Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250

SummaryLung Therapeutics Inc Lung Therapeutics is a pharmaceutical company that offers orphan drug in... See more »
August 14, 2018BioPortfolio

Lung Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250

SummaryLung Therapeutics Inc Lung Therapeutics is a pharmaceutical company that offers orphan drug in... See more »

Lung Therapeutics Press Releases

December 2, 2014BUSINESS WIRE

Lung Therapeutics, Inc. Receives FDA Orphan Drug Designation for Lead Drug Candidate LTI-01

AUSTIN, Texas--(BUSINESS WIRE)--Lung Therapeutics, Inc. has received FDA Orphan Drug Designation for ... See more »
October 28, 2014BUSINESS WIRE

Pharma Start-up Lung Therapeutics, Inc. Achieves Significant Funding to Address Unmet Needs in Lung Injury and Disease

AUSTIN, Texas--(BUSINESS WIRE)--Pharma startup focused on lung injury & disease, Lung Therapeutics cl... See more »

Social Media

Headquarters

2600 Via Fortuna Suite 360

Austin, Texas78746

737-802-1989

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Lung Therapeutics is a pharmaceutical company that researches and develops novel therapeutics for the treatment of lung diseases. Lung Therapeutics was founded in 2013. Lung Therapeutics' headquarters is located in Austin, Texas, USA 78746. It has rai...

CEO

Lung Therapeutics's CEO, Brian Windsor, currently has an approval rating of 89%. Lung Therapeutics's primary competitors are Sanovas, Nuvaira & FibroGen.

Website

lungtx.com

Frequently Asked Questions about Lung Therapeutics

  1. When was Lung Therapeutics founded?

    Lung Therapeutics was founded in 2013
  2. Who is Lung Therapeutics's CEO?

    Lung Therapeutics's CEO is Brian Windsor
  3. How much revenue does Lung Therapeutics generate?

    Lung Therapeutics generates $13M in revenue
  4. How much funding does Lung Therapeutics have?

    Lung Therapeutics has historically raised $57.2M in funding
  1. Where is Lung Therapeutics's headquarters?

    Lung Therapeutics's headquarters is in Austin Texas, USA
  2. How many employees does Lung Therapeutics have?

    Lung Therapeutics has 46 employees
  3. What sector does Lung Therapeutics operate in?

    Lung Therapeutics is in Biotechnology, Pharmaceuticals
  4. Who are Lung Therapeutics's competitors?

    Lung Therapeutics's top competitors are Sanovas, Nuvaira, FibroGen